Amrutanjan Healthcare Reports 7.08% Revenue Growth in Q2FY26 with Strong Pain Management Segment Performance

Amrutanjan Healthcare Limited reported net sales of Rs. 117.70 crores in Q2FY26, representing 7.08% growth compared to Rs. 109.92 crores in Q2FY25. Profit before tax increased 20.51% to Rs. 19.21 crores, while profit after tax grew 14.23% to Rs. 15.94 crores. For H1FY26, net sales reached Rs. 211.75 crores (9.35% growth) with profit before tax rising 36.88% to Rs. 30.51 crores. The pain management segment showed strong performance with overall pain category growing 16% and body category achieving 21% growth. Key growth drivers included Maha Strong (31% growth), Back Pain Roll On (26% growth), and Head Roll On (42% growth). The company's OTC segment generated Rs. 112.80 crores in Q2FY26, while the beverages segment recorded Rs. 4.29 crores (26.55% growth). Comfy brand sales remained flat at Rs. 32.78 crores due to changes in quantity purchase scheme accounting. The company plans to launch premium sanitary pads and revive the JIFFY analgesic brand with Diclofenac topical range. A new sanitary napkin plant is expected to be commissioned by late Q4.

Amrutanjan Healthcare Sets Record Date for First Interim Dividend

Amrutanjan Healthcare Limited has fixed November 18, 2025 as the record date for payment of its first interim dividend for the financial year 2025-26. The dividend will be paid to members whose names appear in the register of members and as beneficial owners as per details from NSDL and CDSL on the record date. The company has informed NSE and BSE about this decision.